Clinical Trial Detail

NCT ID NCT02981342
Title A Study of Abemaciclib (LY2835219) Alone or in Combination With Other Agents in Participants With Previously Treated Pancreatic Ductal Adenocarcinoma
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements no
Sponsors Eli Lilly and Company
Indications

pancreatic ductal adenocarcinoma

Therapies

Capecitabine

Abemaciclib

Gemcitabine

Abemaciclib + LY3023414

Abemaciclib + Galunisertib

Age Groups: senior adult

No variant requirements are available.